Ex vivo Cutaneous Bioavailability of Topical Mometasone Furoate in an O/W Preparation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Skin Pharmacology and Physiology

• Publication date

  2016-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1159/000452743PMID 27925610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bioequivalence of 0.1% mometasone furoate lotion to 0.1% mometasone furoate hydrogel

  2016cited by this paper
• Preclinical and clinical characterization of the cutaneous bioavailability of the hydrophilic phase of a water‐in‐oil emulsion

  2016cited by this paper
• Mometasone furoate-loaded cold processed oil-in-water emulsions: in vitro and in vivo studies

  2015cited by this paper
• Effect of different chitosan derivatives on in vitro scratch wound assay: a comparative study.

  2015cited by this paper
• Cutaneous Drug Delivery of Capsaicin after in vitro Administration of the 8% Capsaicin Dermal Patch System

  2014cited by this paper
• Tachyphylaxis to topical glucocorticoids; what is the evidence?

  2013cited by this paper
• Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1%

  2012cited by this paper
• Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study.

  2012cited by this paper
• Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4.

  2011cited by this paper
• Scratch-wound assay.

  2011cited by this paper
• Topical mometasone furoate for phimosis.

  2010cited by this paper
• Response of cutaneous microcirculation to treatment with mometasone furoate in patients with psoriasis

  2009cited by this paper
• Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris

  2009cited by this paper
• Bioavailability and bioequivalence of topical glucocorticoids.

  2008cited by this paper
• Phimotic ring topical corticoid cream (0.1% mometasone furoate) treatment in children.

  2007cited by this paper
• Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

  2007cited by this paper
• [Topical skin therapy with glucocorticoids--therapeutic index].

  2004cited by this paper
• Topical Glucocorticoid Therapy Directly Induces Up-Regulation of Functional CXCR4 on Primed T Lymphocytes in the Aqueous Humor of Patients with Uveitis1

  2004cited by this paper
• Efficacy of mometasone furoate microemulsion in the treatment of erosive-ulcerative oral lichen planus: pilot study.

  2004cited by this paper
• Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.

  2004cited by this paper
• Topical mometasone furoate for vulvar lichen sclerosus.

  2003cited by this paper
• Mometasone furoate degradation and metabolism in human biological fluids and tissues

  2003cited by this paper
• Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema

  2003cited by this paper
• Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology

  2002cited by this paper
• Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream.

  2002cited by this paper
• Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.

  2002cited by this paper
• A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.

  2001cited by this paper
• Mometasone furoate is a safe topical corticosteroid?

  2000cited by this paper
• An open study of efficacy and safety of long‐term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis

  2000cited by this paper
• Topical mometasone furoate for the treatment of childhood vltiligo.

  1999cited by this paper
• Treatment of recurrent oral ulcers with mometasone furoate lotion

  1999cited by this paper
• Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone

  1998cited by this paper
• Effects of Mometasone Furoate on Human Keratinocytes and Fibroblasts in vitro

  1998cited by this paper
• Topical glucocorticoids and the skin--mechanisms of action: an update.

  1998cited by this paper
• Topical Glucocorticoids with Improved Risk-Benefit Ratio

  1996cited by this paper
• Human keratinocyte isolation and cell culture: a survey of current practices in the UK.

  1996cited by this paper
• A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin

  1995cited by this paper
• Topical mometasone furoate and betamethasone‐17‐valerate decrease collagen synthesis to a similar extent in human skin in vivo

  1995cited by this paper
• In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.

  1995cited by this paper
• Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts

  1995cited by this paper
• Topical momethasone furoate and betamethasone-17-valerate decrease similarly collagen synthesis in human skin in vivo

  1994cited by this paper
• Side effects of topical glucocorticoids.

  1993cited by this paper
• Metabolism of topical drugs within the skin, in particular glucocorticoids.

  1993cited by this paper
• Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue.

  1993cited by this paper
• Topical glucocorticoids with improved benefit/risk ratio: do they exist?

  1992cited by this paper
• Once-Daily 0.1% Mometasone Furoate Cream versus Twice-Daily 0.1% Betamethasone Valerate Cream in the Treatment of a Variety of Dermatoses

  1990cited by this paper
• Relation of application time to bioactivity of a potent topical glucocorticoid formulation.

  1990cited by this paper
• Mometasone Furoate Ointment 0.1% vs. Hydrocortisone Ointment 1.0% in Psoriasis

  1989cited by this paper
• Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.

  1988cited by this paper
• [Classification of external corticoids].

  1983cited by this paper

• Validation of a HPLC-UV method for the quantification of budesonide in skin layers.

  2020cites this paper
• S2k guidelines for the use of topical preparations on the skin

  2018cites this paper
• S2k‐Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika)

  2018cites this paper